A citation-based method for searching scientific literature

Balazs Halmos, Thomas Burke, Chrysostomos Kalyvas, Kristel Vandormael, Andrew Frederickson, Bilal Piperdi. Lung Cancer 2021
Times Cited: 6







List of co-cited articles
6 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


A Matching-Adjusted Indirect Comparison of Pembrolizumab + Chemotherapy vs. Nivolumab + Ipilimumab as First-Line Therapies in Patients with PD-L1 TPS ≥1% Metastatic NSCLC.
Balazs Halmos, Thomas Burke, Chrysostomos Kalyvas, Ralph Insinga, Kristel Vandormael, Andrew Frederickson, Bilal Piperdi. Cancers (Basel) 2020
8
50

Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research.
James E Signorovitch, Vanja Sikirica, M Haim Erder, Jipan Xie, Mei Lu, Paul S Hodgkins, Keith A Betts, Eric Q Wu. Value Health 2012
179
33

Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves.
Patricia Guyot, A E Ades, Mario J N M Ouwens, Nicky J Welton. BMC Med Res Methodol 2012
996
33

Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.
Martin Reck, Delvys Rodríguez-Abreu, Andrew G Robinson, Rina Hui, Tibor Csőszi, Andrea Fülöp, Maya Gottfried, Nir Peled, Ali Tafreshi, Sinead Cuffe,[...]. N Engl J Med 2016
33

Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer.
Shirish Gadgeel, Delvys Rodríguez-Abreu, Giovanna Speranza, Emilio Esteban, Enriqueta Felip, Manuel Dómine, Rina Hui, Maximilian J Hochmair, Philip Clingan, Steven F Powell,[...]. J Clin Oncol 2020
392
33

Occult Gastrointestinal Perforation in a Patient With EGFR-Mutant Non-Small-Cell Lung Cancer Receiving Combination Chemotherapy With Atezolizumab and Bevacizumab: Brief Report.
Ashray Gunjur, Geoff Chong, Adeline Lim, Eddie Lau, Paul Mitchell, Thomas John, Surein Arulananda. Clin Lung Cancer 2020
4
50

The adverse events associated with combination immunotherapy in cancers: Challenges and chances.
Minglei Zhuo, Yujia Chi, Ziping Wang. Asia Pac J Clin Oncol 2020
7
16

Immunotherapy in metastatic melanoma: a novel scenario of new toxicities and their management.
Ester Simeone, Antonio M Grimaldi, Lucia Festino, Claudia Trojaniello, Maria G Vitale, Vito Vanella, Marco Palla, Paolo A Ascierto. Melanoma Manag 2019
14
16

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial.
Tony S K Mok, Yi-Long Wu, Iveta Kudaba, Dariusz M Kowalski, Byoung Chul Cho, Hande Z Turna, Gilberto Castro, Vichien Srimuninnimit, Konstantin K Laktionov, Igor Bondarenko,[...]. Lancet 2019
16

Pembrolizumab plus chemotherapy for first-line treatment of metastatic nonsquamous non-small-cell lung cancer: a network meta-analysis.
Andrew M Frederickson, Stella Arndorfer, Ina Zhang, Maria Lorenzi, Ralph Insinga, Ashwini Arunachalam, Thomas A Burke, George R Simon. Immunotherapy 2019
35
16

A comprehensive review of nongenetic prognostic and predictive factors influencing the heterogeneity of outcomes in advanced non-small-cell lung cancer.
Gebra Cuyún Carter, Amy M Barrett, James A Kaye, Astra M Liepa, Katherine B Winfree, William J John. Cancer Manag Res 2014
37
16

Histology as a treatment effect modifier in advanced non-small cell lung cancer: a systematic review of the evidence.
Lachlan Standfield, Adèle R Weston, Helen Barraclough, Maximiliano Van Kooten, Nick Pavlakis. Respirology 2011
20
16


Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study.
Michael Boyer, Mehmet A N Şendur, Delvys Rodríguez-Abreu, Keunchil Park, Dae Ho Lee, Irfan Çiçin, Perran Fulden Yumuk, Francisco J Orlandi, Ticiana A Leal, Olivier Molinier,[...]. J Clin Oncol 2021
65
16

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.
Hossein Borghaei, Luis Paz-Ares, Leora Horn, David R Spigel, Martin Steins, Neal E Ready, Laura Q Chow, Everett E Vokes, Enriqueta Felip, Esther Holgado,[...]. N Engl J Med 2015
16

Nivolumab plus ipilimumab versus pembrolizumab as chemotherapy-free, first-line treatment for PD-L1-positive non-small cell lung cancer.
Yixin Zhou, Yaqiong Zhang, Guifang Guo, Xiuyu Cai, Hui Yu, Yanyu Cai, Bei Zhang, Shaodong Hong, Li Zhang. Clin Transl Med 2020
17
16


PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project.
Fred R Hirsch, Abigail McElhinny, Dave Stanforth, James Ranger-Moore, Malinka Jansson, Karina Kulangara, William Richardson, Penny Towne, Debra Hanks, Bharathi Vennapusa,[...]. J Thorac Oncol 2017
855
16

The evolving immuno-oncology landscape in advanced lung cancer: first-line treatment of non-small cell lung cancer.
Jia Li Low, Robert J Walsh, Yvonne Ang, Gloria Chan, Ross A Soo. Ther Adv Med Oncol 2019
33
16

Performance status and smoking status are independent favorable prognostic factors for survival in non-small cell lung cancer: a comprehensive analysis of 26,957 patients with NSCLC.
Tomoya Kawaguchi, Minoru Takada, Akihito Kubo, Akihide Matsumura, Shimao Fukai, Atsuhisa Tamura, Ryusei Saito, Yosihito Maruyama, Masaaki Kawahara, Sai-Hong Ignatius Ou. J Thorac Oncol 2010
190
16

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.
Roy S Herbst, Paul Baas, Dong-Wan Kim, Enriqueta Felip, José L Pérez-Gracia, Ji-Youn Han, Julian Molina, Joo-Hang Kim, Catherine Dubos Arvis, Myung-Ju Ahn,[...]. Lancet 2016
16

Comparative effectiveness without head-to-head trials: a method for matching-adjusted indirect comparisons applied to psoriasis treatment with adalimumab or etanercept.
James E Signorovitch, Eric Q Wu, Andrew P Yu, Charles M Gerrits, Evan Kantor, Yanjun Bao, Shiraz R Gupta, Parvez M Mulani. Pharmacoeconomics 2010
162
16

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline.
Julie R Brahmer, Christina Lacchetti, Bryan J Schneider, Michael B Atkins, Kelly J Brassil, Jeffrey M Caterino, Ian Chau, Marc S Ernstoff, Jennifer M Gardner, Pamela Ginex,[...]. J Clin Oncol 2018
16

The biology and management of non-small cell lung cancer.
Roy S Herbst, Daniel Morgensztern, Chris Boshoff. Nature 2018
16

Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.
Matthew D Hellmann, Luis Paz-Ares, Reyes Bernabe Caro, Bogdan Zurawski, Sang-We Kim, Enric Carcereny Costa, Keunchil Park, Aurelia Alexandru, Lorena Lupinacci, Emmanuel de la Mora Jimenez,[...]. N Engl J Med 2019
16




Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.
Marina C Garassino, Shirish Gadgeel, Emilio Esteban, Enriqueta Felip, Giovanna Speranza, Manuel Domine, Maximilian J Hochmair, Steven Powell, Susanna Yee-Shan Cheng, Helge G Bischoff,[...]. Lancet Oncol 2020
76
16

Atezolizumab in combination with bevacizumab, paclitaxel and carboplatin for the first-line treatment of patients with metastatic non-squamous non-small cell lung cancer, including patients with EGFR mutations.
Martin Reck, Geetha Shankar, Anthony Lee, Shelley Coleman, Mark McCleland, Vassiliki A Papadimitrakopoulou, Mark A Socinski, Alan Sandler. Expert Rev Respir Med 2020
40
16

Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial.
Luis Paz-Ares, Filippo de Marinis, Mircea Dediu, Michael Thomas, Jean-Louis Pujol, Paolo Bidoli, Olivier Molinier, Tarini Prasad Sahoo, Eckart Laack, Martin Reck,[...]. Lancet Oncol 2012
441
16

Randomized phase III trial comparing switch-maintenance pemetrexed with observation followed by pemetrexed at progression in advanced NSCLC.
Tarje O Halvorsen, Kristin Stokke, Kristin T Killingberg, Sunil X Raj, Sveinung Sørhaug, Odd Terje Brustugun, Øystein Fløtten, Nina Helbekkmo, Kjersti Hornslien, Tesfaye Madebo,[...]. Acta Oncol 2020
5
20


The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies.
Giorgio Scagliotti, Nasser Hanna, Frank Fossella, Katherine Sugarman, Johannes Blatter, Patrick Peterson, Lorinda Simms, Frances A Shepherd. Oncologist 2009
550
16

First-line carboplatin plus pemetrexed with pemetrexed maintenance in HIV-positive patients with advanced non-squamous non-small cell lung cancer: the phase II IFCT-1001 CHIVA trial.
Armelle Lavole, Laurent Greillier, Julien Mazières, Isabelle Monnet, Lize Kiakouama-Maleka, Xavier Quantin, Jean Philippe Spano, Herve Lena, Philippe Fraisse, Henri Janicot,[...]. Eur Respir J 2020
7
16

Treatment Decisions for Advanced Non-Squamous Non-Small Cell Lung Cancer: Patient and Physician Perspectives on Maintenance Therapy.
Suzanne McMullen, Lisa M Hess, Edward S Kim, Benjamin Levy, Mohamed Mohamed, David Waterhouse, Antoinette Wozniak, Sarah Goring, Kerstin Müller, Catherine Muehlenbein,[...]. Patient 2019
17
16

Treatment patterns, duration and outcomes of pemetrexed maintenance therapy in patients with advanced NSCLC in a real-world setting.
Katherine B Winfree, Aracelis Z Torres, Yajun Emily Zhu, Catherine Muehlenbein, Himani Aggarwal, Susan Woods, Amy Abernethy. Curr Med Res Opin 2019
10
16

Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma.
Jacek Jassem, Rodryg Ramlau, Armando Santoro, Wolfgang Schuette, Assad Chemaissani, Shengyan Hong, Johannes Blatter, Susumu Adachi, Axel Hanauske, Christian Manegold. J Clin Oncol 2008
161
16

24-Month Overall Survival from KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non-Small Cell Lung Cancer.
Hossein Borghaei, Corey J Langer, Shirish Gadgeel, Vassiliki A Papadimitrakopoulou, Amita Patnaik, Steven F Powell, Ryan D Gentzler, Renato G Martins, James P Stevenson, Shadia I Jalal,[...]. J Thorac Oncol 2019
154
16


Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.
Mark A Socinski, Robert M Jotte, Federico Cappuzzo, Francisco Orlandi, Daniil Stroyakovskiy, Naoyuki Nogami, Delvys Rodríguez-Abreu, Denis Moro-Sibilot, Christian A Thomas, Fabrice Barlesi,[...]. N Engl J Med 2018
16

First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial.
Luis Paz-Ares, Tudor-Eliade Ciuleanu, Manuel Cobo, Michael Schenker, Bogdan Zurawski, Juliana Menezes, Eduardo Richardet, Jaafar Bennouna, Enriqueta Felip, Oscar Juan-Vidal,[...]. Lancet Oncol 2021
329
16

Multicenter phase II study on cisplatin, pemetrexed, and bevacizumab followed by maintenance with pemetrexed and bevacizumab for patients with advanced or recurrent nonsquamous non-small cell lung cancer: MAP study.
Yasuhiro Tsutani, Yoshihiro Miyata, Takeshi Masuda, Kazunori Fujitaka, Mihoko Doi, Yoshikazu Awaya, Shoichi Kuyama, Soichi Kitaguchi, Kazuhiro Ueda, Noboru Hattori,[...]. BMC Cancer 2018
8
16

Renal impairment during pemetrexed maintenance in patients with advanced nonsmall cell lung cancer: a cohort study.
Sabine Visser, Jeannine Huisbrink, Nils E van 't Veer, Jermo J van Toor, Anton J M van Boxem, Nico C van Walree, Bruno H Stricker, Joachim G J V Aerts. Eur Respir J 2018
18
16


Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Roberto Ferrara, Martina Imbimbo, Reem Malouf, Sophie Paget-Bailly, François Calais, Corynne Marchal, Virginie Westeel. Cochrane Database Syst Rev 2020
23
16

Cost-effectiveness of Atezolizumab Combination Therapy for First-Line Treatment of Metastatic Nonsquamous Non-Small Cell Lung Cancer in the United States.
Steven D Criss, Meghan J Mooradian, Tina R Watson, Justin F Gainor, Kerry L Reynolds, Chung Yin Kong. JAMA Netw Open 2019
35
16

Final efficacy and safety results of pemetrexed continuation maintenance therapy in the elderly from the PARAMOUNT phase III study.
Cesare Gridelli, Filippo de Marinis, Michael Thomas, Kumar Prabhash, Claude El Kouri, Fiona Blackhall, Frederique Bustin, Jean-Louis Pujol, William J John, Belen San Antonio,[...]. J Thorac Oncol 2014
36
16

Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study.
Corey J Langer, Shirish M Gadgeel, Hossein Borghaei, Vassiliki A Papadimitrakopoulou, Amita Patnaik, Steven F Powell, Ryan D Gentzler, Renato G Martins, James P Stevenson, Shadia I Jalal,[...]. Lancet Oncol 2016
980
16



Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.